An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder that causes chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Samkari, Hanny, Kasthuri, Raj S., Parambil, Joseph G., Albitar, Hasan A., Almodallal, Yahya A., Vázquez, Carolina, Serra, Marcelo M., Dupuis-Girod, Sophie, Wilsen, Craig B., McWilliams, Justin P., Fountain, Evan H., Gossage, James R., Weiss, Clifford R., Latif, Muhammad A., Issachar, Assaf, Mei-Zahav, Meir, Meek, Mary E., Conrad, Miles, Rodriguez-Lopez, Josanna, Kuter, David J., Iyer, Vivek N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327711/
https://www.ncbi.nlm.nih.gov/pubmed/32675221
http://dx.doi.org/10.3324/haematol.2020.261859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327711/
https://www.ncbi.nlm.nih.gov/pubmed/32675221
http://dx.doi.org/10.3324/haematol.2020.261859

Ejemplares similares